Characteristics of patients with schizophrenia switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M): a systematic review

Li, Qian; Li, Xin; Ye, Chong; Jia, Miaomiao; Si, Tianmei

doi:10.1186/s12888-024-05508-6

Table 1 Characteristics of included studies

From: Characteristics of patients with schizophrenia switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M): a systematic review

Study	Country	Study design	Sample size	Outcomes	Other information	Quality assessment by RoB2^c	Quality assessment by NOS^d	Quality assessment by NIH^e	Quality assessment by QUIPS^f
Bozzatello 2019 [34]	Italy	Randomized controlled trial	33	CGI-S, PSP	ACTRN12618001113246	High	NA	NA	NA
Kim 2021 [6]	Korea	Observational study	1,166	CGI-S, PSP	Post marketing surveillance data	NA	NA	NA	High
Li 2016 [37, 38, 47, 49]	Asia	Pre-post trial	212	PANSS, CGI-S, PSP	NCT01527305	NA	NA	Good	NA
Li 2018 [24]	China	Pre-post trial (Multivariate analysis)	610	PANSS, CGI-S, PSP	NCT01685931 post hoc analysis during acute treatment phase	NA	NA	NA	Low
Magliocco 2020 [40]	Italy	Observational study	12	PANSS, PSP	Real-word study	NA	8	NA	NA
Patel 2020 [41]	USA	Observational study	177	Hospitalization rate	Real-word analysis	NA	NA	Fair	NA
Peitl 2022 [42]	Croatia	Observational study	112	CGI-S	Real-word study	NA	NA	Fair	NA
Schreiner 2014 [35, 36, 43, 44]	21 countries^a	Pre-post trial	593	PANSS, CGI-S, PSP	NCT01281527 subset of nonacute patients	NA	NA	Fair	NA
Si 2016 [45]	China	Pre-post trial	608	PANSS, CGI-S, PSP	NCT01685931 acute treatment phase	NA	NA	Fair	NA
Sliwa 2011 [29]	USA, Europe, and Asia	Post hoc RCT	106	PANSS, CGI-S, PSP	NCT00590577 post hoc analysis	Low	NA	NA	NA
Zhang 2015 [39, 46, 48, 49]	Asia–Pacific^b	Pre-post trial	521	PANSS, CGI-S, PSP Hospitalization rate	NCT01051531	NA	NA	Fair	NA

Abbreviations: CGI-S Clinical global impression-severity, NA Not applicable, NIH National Institutes of Health, NOS Newcastle-Ottawa Scale, PANSS Positive and negative syndrome scale, PSP Personal and social performance, RCT Randomised controlled trial, RoB2 Risk of bias tool 2
^a21 countries included Austria, Belgium, Croatia, Denmark, Estonia, France, Germany, Greece, Hungary, Israel, Italy, Latvia, Lithuania, The Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey, Ukraine, and the United Kingdom
^b87.2% patients from Asian countries and 12.8% from Australia and New Zealand
^cQuality assessment results of RCTs using RoB2. Overall quality is rated as low, high, or unclear. ‘NA’ in this column means the study is not an RCT and is not applicable to be assessed using RoB2
^dQuality assessment results of non-randomised trials and cohort studies using NOS. The maximum score is 9. Higher score indicates better quality. ‘NA’ in this column means the study is not a cohort study and thus is not applicable to be assessed using NOS
^eQuality assessment results of before and after trials using NIH. Quality was rated as poor (0-4 out of 12 questions), fair (5-8 out of 12 questions), or good (9-12 out of 12 questions). ‘NA’ in this column means the study is not a before and after study and thus is not applicable to be assessed using NIH
^fQuality assessment results of prognostic studies using QUIPS. ‘NA’ in this column means the study is not a prognostic study and thus is not applicable to be assessed using QUIPS

Back to article page

ISSN: 1471-244X

Contact us

Submission enquiries: bmcpsychiatry@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Psychiatry

Contact us